Johnson & Johnson exceeded analysts’ expectations in Q2 2025, driven by medical device sales reaching $8.54 billion and a remarkable 22.3% growth in cardiology. Innovative medicines revenue grew 4.9% despite Stelara’s patent expiration leading to a 43% sales drop to $1.7 billion. Oncology products like Darzalex and Carvykti showed robust gains, contributing to a companywide 6% sales increase to $23.7 billion. CEO Joaquin Duato reaffirmed ambitions for J&J to become the leading oncology company by 2030 with sales surpassing $50 billion annually.